Symbols / KZIA $7.34 +2.23% Kazia Therapeutics Limited

Healthcare • Biotechnology • Australia • NCM
KZIA Chart
About

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 83.87M
Enterprise Value 41.53B Income -22.80M Sales 1.90M
Book/sh 2.84 Cash/sh 0.01 Dividend Yield —
Payout 0.00% Employees 6 IPO —
P/E — Forward P/E -955.59 PEG —
P/S 44.18 P/B 2.59 P/C —
EV/EBITDA -2328.04 EV/Sales 21875.62 Quick Ratio 2.86
Current Ratio 2.87 Debt/Eq 0.21 LT Debt/Eq —
EPS (ttm) -7.36 EPS next Y -0.01 EPS Growth —
Revenue Growth 3.12% Earnings — ROA -25.70%
ROE -106.90% ROIC — Gross Margin 100.00%
Oper. Margin -146.41% Profit Margin 0.00% Shs Outstand 11.43M
Shs Float 3.91B Short Float 0.39% Short Ratio 0.23
Short Interest — 52W High 17.40 52W Low 2.86
Beta 1.62 Avg Volume 188.98K Volume 28.53K
Target Price $18.86 Recom None Prev Close $7.18
Price $7.34 Change 2.23%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$18.87
Mean price target
2. Current target
$7.34
Latest analyst target
3. DCF / Fair value
$1.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.34
Low
$17.87
High
$19.86
Mean
$18.87

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-28 reit HC Wainwright & Co. Buy → Buy $18
2025-12-12 main HC Wainwright & Co. Buy → Buy $18
2025-10-02 main Maxim Group Buy → Buy $20
2025-07-10 main HC Wainwright & Co. Buy → Buy $13
2025-06-11 main Maxim Group Buy → Buy $15
2025-02-06 init Maxim Group — → Buy $3
2024-07-12 reit HC Wainwright & Co. Buy → Buy $2
2023-04-11 up HC Wainwright & Co. Neutral → Buy $2
2022-08-02 down Maxim Group Buy → Hold —
2022-08-02 down HC Wainwright & Co. Buy → Neutral —
2021-10-14 init Maxim Group — → Buy $18
2021-01-05 init HC Wainwright & Co. — → Buy $17
News
RSS: Latest KZIA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.04
-98.18%
2.31
0.00
0.00
Operating Revenue
0.04
-98.18%
2.31
0.00
0.00
Operating Expense
14.26
-53.66%
30.77
+27.43%
24.15
-4.93%
25.40
Research And Development
7.33
-57.85%
17.38
+11.67%
15.56
-22.83%
20.17
Selling General And Administration
8.72
-35.71%
13.56
+58.02%
8.58
+63.80%
5.24
Selling And Marketing Expense
—
0.00
0.00
-100.00%
0.13
General And Administrative Expense
8.72
-35.71%
13.56
+58.02%
8.58
+67.87%
5.11
Other Gand A
8.72
-35.71%
13.56
+58.02%
8.58
+67.87%
5.11
Other Operating Expenses
-1.79
-932.95%
-0.17
-17200.00%
-0.00
+90.00%
-0.01
Total Expenses
14.26
-53.66%
30.77
+27.43%
24.15
-4.93%
25.40
Operating Income
-14.22
+50.05%
-28.46
-17.87%
-24.15
+4.93%
-25.40
EBITDA
-13.28
+50.05%
-26.59
-19.37%
-22.28
+5.33%
-23.53
Normalized EBITDA
-7.46
+72.08%
-26.71
-4.08%
-25.66
-9.00%
-23.55
Reconciled Depreciation
0.93
-50.03%
1.87
+0.00%
1.87
+0.00%
1.87
EBIT
-14.22
+50.05%
-28.46
-17.87%
-24.15
+4.93%
-25.40
Total Unusual Items
-5.83
-4994.96%
0.12
-96.49%
3.39
+22486.67%
0.01
Total Unusual Items Excluding Goodwill
-5.83
-4994.96%
0.12
-96.49%
3.39
+22486.67%
0.01
Special Income Charges
-5.83
-4994.96%
0.12
-96.49%
3.39
+22486.67%
0.01
Impairment Of Capital Assets
13.38
0.00
0.00
—
Restructuring And Mergern Acquisition
-7.55
-6247.90%
-0.12
+96.49%
-3.39
0.00
Write Off
—
0.00
0.00
+100.00%
-0.01
Net Income
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Pretax Income
-22.45
+17.01%
-27.05
-30.44%
-20.74
+18.30%
-25.38
Net Non Operating Interest Income Expense
0.07
+500.00%
0.01
-45.45%
0.02
+1000.00%
0.00
Net Interest Income
0.07
+500.00%
0.01
-45.45%
0.02
+1000.00%
0.00
Interest Income Non Operating
0.07
+500.00%
0.01
-45.45%
0.02
+1000.00%
0.00
Interest Income
0.07
+500.00%
0.01
-45.45%
0.02
+1000.00%
0.00
Other Income Expense
-8.30
-692.65%
1.40
-58.65%
3.39
+22486.67%
0.01
Other Non Operating Income Expenses
-2.48
-293.29%
1.28
+128100.00%
0.00
—
Tax Provision
-1.75
-544.28%
-0.27
+0.00%
-0.27
+26.36%
-0.37
Tax Rate For Calcs
0.00
+676.32%
0.00
-23.34%
0.00
-9.86%
0.00
Tax Effect Of Unusual Items
-0.45
-38101.21%
0.00
-97.31%
0.04
+20259.85%
0.00
Net Income Including Noncontrolling Interests
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Net Income From Continuing Operation Net Minority Interest
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Net Income From Continuing And Discontinued Operation
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Net Income Continuous Operations
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Normalized Income
-15.33
+43.00%
-26.90
-12.97%
-23.81
+4.87%
-25.03
Net Income Common Stockholders
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Diluted EPS
-18.90
+62.80%
-50.80
+9.53%
-56.15
+39.66%
-93.05
Basic EPS
-18.90
+62.80%
-50.80
+9.53%
-56.15
+39.66%
-93.05
Basic Average Shares
1.10
+107.81%
0.53
+43.08%
0.37
+39.12%
0.26
Diluted Average Shares
1.10
+107.81%
0.53
+43.08%
0.37
+39.12%
0.26
Diluted NI Availto Com Stockholders
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Gain On Sale Of PPE
—
—
—
—
Other Taxes
—
—
0.00
0.00
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
6.06
-71.92%
21.59
-23.14%
28.08
-21.75%
35.89
Current Assets
4.93
-19.71%
6.14
-42.95%
10.77
+14.00%
9.45
Cash Cash Equivalents And Short Term Investments
4.34
+162.22%
1.66
-68.38%
5.24
-28.80%
7.36
Cash And Cash Equivalents
4.34
+162.22%
1.66
-68.38%
5.24
-28.80%
7.36
Cash Equivalents
—
—
—
0.00
Cash Financial
4.34
+162.22%
1.66
-68.38%
5.24
-28.80%
7.36
Receivables
0.09
-32.33%
0.13
+26.67%
0.10
+105.88%
0.05
Accounts Receivable
—
0.00
-100.00%
0.00
0.00
Other Receivables
0.09
-32.33%
0.13
+27.88%
0.10
+103.92%
0.05
Taxes Receivable
—
—
—
—
Prepaid Assets
0.50
-88.54%
4.36
-19.74%
5.43
+166.37%
2.04
Other Current Assets
—
—
—
—
Total Non Current Assets
1.13
-92.70%
15.44
-10.81%
17.31
-34.52%
26.44
Goodwill And Other Intangible Assets
1.09
-92.94%
15.40
-10.82%
17.27
-9.77%
19.14
Other Intangible Assets
1.09
-92.94%
15.40
-10.82%
17.27
-9.77%
19.14
Non Current Prepaid Assets
0.04
+0.00%
0.04
-6.98%
0.04
-99.41%
7.30
Total Liabilities Net Minority Interest
14.36
-54.55%
31.60
+97.09%
16.03
-8.97%
17.61
Current Liabilities
14.05
-45.52%
25.80
+241.00%
7.57
+12.44%
6.73
Payables And Accrued Expenses
10.12
-32.85%
15.07
+248.05%
4.33
+15.16%
3.76
Payables
5.64
+24.12%
4.55
+430.69%
0.86
-43.77%
1.52
Accounts Payable
5.64
+24.12%
4.55
+430.69%
0.86
-43.77%
1.52
Other Payable
—
—
—
2.24
Current Accrued Expenses
4.47
-57.49%
10.52
+202.97%
3.47
+55.35%
2.23
Employee Benefits
0.04
+5.71%
0.04
-40.68%
0.06
-49.57%
0.12
Pensionand Other Post Retirement Benefit Plans Current
0.39
+6.85%
0.36
-47.10%
0.69
+86.99%
0.37
Current Debt And Capital Lease Obligation
0.40
-37.54%
0.63
-64.70%
1.80
-2.44%
1.84
Current Debt
0.40
-37.54%
0.63
-64.70%
1.80
-2.44%
1.84
Other Current Borrowings
0.40
-37.54%
0.63
-64.70%
1.80
—
Other Current Liabilities
3.15
-67.63%
9.73
+1197.47%
0.75
-1.19%
0.76
Total Non Current Liabilities Net Minority Interest
0.31
-94.68%
5.80
-31.46%
8.47
-22.20%
10.89
Non Current Deferred Liabilities
0.27
-86.52%
2.02
-11.84%
2.29
-10.59%
2.56
Non Current Deferred Taxes Liabilities
0.27
-86.52%
2.02
-11.84%
2.29
-10.59%
2.56
Other Non Current Liabilities
—
3.75
-38.70%
6.12
-25.44%
8.21
Stockholders Equity
-8.30
+17.13%
-10.02
-183.13%
12.05
-34.06%
18.27
Common Stock Equity
-8.30
+17.13%
-10.02
-183.13%
12.05
-34.06%
18.27
Capital Stock
123.05
+21.06%
101.64
+4.30%
97.45
+15.36%
84.48
Common Stock
123.05
+21.06%
101.64
+4.30%
97.45
+15.36%
84.48
Share Issued
809.42
+143.18%
332.85
+45.97%
228.03
+64.34%
138.76
Ordinary Shares Number
809.42
+143.18%
332.85
+45.97%
228.03
+64.34%
138.76
Additional Paid In Capital
0.38
0.00
0.00
0.00
Retained Earnings
-134.83
-17.11%
-115.13
-29.24%
-89.08
-29.83%
-68.62
Gains Losses Not Affecting Retained Earnings
3.10
-10.79%
3.48
-5.60%
3.68
+52.61%
2.41
Total Equity Gross Minority Interest
-8.30
+17.13%
-10.02
-183.13%
12.05
-34.06%
18.27
Total Capitalization
-8.30
+17.13%
-10.02
-183.13%
12.05
-34.06%
18.27
Working Capital
-9.12
+53.60%
-19.65
-712.78%
3.21
+17.86%
2.72
Invested Capital
-7.91
+15.75%
-9.38
-167.77%
13.85
-31.17%
20.12
Total Debt
0.40
-37.54%
0.63
-64.70%
1.80
-2.44%
1.84
Net Tangible Assets
-9.39
+63.06%
-25.42
-387.01%
-5.22
-504.05%
-0.86
Tangible Book Value
-9.39
+63.06%
-25.42
-387.01%
-5.22
-504.05%
-0.86
Other Equity Interest
—
—
—
—
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-13.28
-38.59%
-9.58
+36.78%
-15.16
+33.42%
-22.76
Cash Flow From Continuing Operating Activities
-13.28
-38.59%
-9.58
+36.78%
-15.16
+33.42%
-22.76
Net Income From Continuing Operations
-20.70
+22.69%
-26.78
-30.85%
-20.46
+18.19%
-25.01
Depreciation Amortization Depletion
0.93
-50.03%
1.87
+0.00%
1.87
+0.00%
1.87
Amortization Cash Flow
0.93
-50.03%
1.87
+0.00%
1.87
+0.00%
1.87
Depreciation And Amortization
0.93
-50.03%
1.87
+0.00%
1.87
+0.00%
1.87
Amortization Of Intangibles
0.93
-50.03%
1.87
+0.00%
1.87
+0.00%
1.87
Other Non Cash Items
-5.83
-195.59%
6.09
+390.65%
-2.10
-1479.61%
0.15
Stock Based Compensation
0.65
+22.51%
0.53
-54.01%
1.16
-30.81%
1.68
Asset Impairment Charge
13.38
0.00
0.00
—
Operating Gains Losses
0.31
+1650.00%
-0.02
-143.48%
0.05
+102.14%
-2.15
Unrealized Gain Loss On Investment Securities
0.98
+176.60%
-1.28
0.00
0.00
Net Foreign Currency Exchange Gain Loss
0.31
+1650.00%
-0.02
-143.48%
0.05
+102.14%
-2.15
Change In Working Capital
-3.01
-130.07%
10.00
+130.89%
4.33
+402.55%
0.86
Change In Receivables
3.80
+75880.00%
0.01
-99.86%
3.45
+49385.71%
-0.01
Changes In Account Receivables
3.80
+75880.00%
0.01
-99.86%
3.45
+57600.00%
-0.01
Change In Prepaid Assets
—
—
0.36
-76.66%
1.56
Change In Payables And Accrued Expense
-4.95
-146.10%
10.74
+1787.17%
0.57
+207.77%
-0.53
Change In Payable
-4.95
-146.10%
10.74
+1787.17%
0.57
+207.77%
-0.53
Change In Other Working Capital
-1.72
-177.26%
-0.62
-8757.14%
-0.01
+95.81%
-0.17
Change In Other Current Assets
0.10
-90.39%
1.04
+185.21%
0.36
+231.77%
-0.28
Change In Other Current Liabilities
-0.24
+79.52%
-1.16
-2482.22%
-0.04
-102.44%
1.84
Investing Cash Flow
—
0.00
0.00
+100.00%
-2.37
Cash Flow From Continuing Investing Activities
—
0.00
0.00
+100.00%
-2.37
Net Investment Purchase And Sale
—
—
—
—
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
—
—
-2.37
Purchase Of Business
—
—
—
-2.37
Net Other Investing Changes
—
—
—
-2.37
Financing Cash Flow
15.98
+167.03%
5.99
-53.86%
12.97
+248.15%
3.73
Cash Flow From Continuing Financing Activities
15.98
+167.03%
5.99
-53.86%
12.97
+248.15%
3.73
Net Issuance Payments Of Debt
0.00
-100.00%
0.41
0.00
0.00
Issuance Of Debt
0.00
-100.00%
0.78
0.00
0.00
Repayment Of Debt
0.00
+100.00%
-0.37
0.00
0.00
Short Term Debt Issuance
0.00
-100.00%
0.78
0.00
0.00
Short Term Debt Payments
0.00
+100.00%
-0.37
0.00
0.00
Net Short Term Debt Issuance
0.00
-100.00%
0.41
0.00
0.00
Net Common Stock Issuance
14.80
+165.30%
5.58
-56.98%
12.97
+248.15%
3.73
Proceeds From Stock Option Exercised
1.18
0.00
0.00
—
Changes In Cash
2.70
+175.19%
-3.60
-64.65%
-2.18
+89.79%
-21.40
Effect Of Exchange Rate Changes
-0.02
-233.33%
0.01
-81.25%
0.06
-94.55%
1.18
Beginning Cash Position
1.66
-68.38%
5.24
-28.80%
7.36
-73.32%
27.59
End Cash Position
4.34
+162.22%
1.66
-68.38%
5.24
-28.80%
7.36
Free Cash Flow
-13.28
-38.59%
-9.58
+36.78%
-15.16
+33.42%
-22.76
Common Stock Issuance
14.80
+165.30%
5.58
-56.98%
12.97
+248.15%
3.73
Issuance Of Capital Stock
14.80
+165.30%
5.58
-56.98%
12.97
+248.15%
3.73
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category